Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MALACHITE I in treatment-naive adults with chronic hepatitis C genotype 1
2012-003754-84Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ombitasvir + paritaprevir + ritonavir, dasabuvir, ribavirin, telaprevir, peginterferon alfa-2a in chronic hepatitis C (CHC), sponsored by AbbVie Inc.. Started Mar 2013; status: completed.
02
Drugs
ombitasvir + paritaprevir + ritonavirdasabuvirribavirintelaprevirpeginterferon alfa-2a
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2012-003754-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003754-84.